Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK Flu/COVID-19 mRNA Combination Vaccine Study
NCT06680375Phase 1Completed
- Sponsor
- GSK
- Start
- Nov 2024
- Primary completion
- Jun 2025
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and influenza (6 arms), sponsored by GSK. Primary endpoints: Percentage of participants with increase in grading for at least one laboratory value, Percentage of participants with solicited administration site adverse events and 8 more. Started Nov 2024; status: completed.
02
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on NCT06680375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06680375.